Sarepta Shareholders Approve 2026 Equity and ESPP Plans
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The latest update is out from Sarepta Therapeutics ( (SRPT) ).
On June 4, 2026, Sarepta Therapeutics stockholders approved a new 2026 Equity Incentive Plan, replacing the 2018 plan and authorizing up to 6,286,841 shares for equity awards, along with a 2026 Employee Stock Purchase Plan that replaces the prior 2013 plan and provides 1,500,000 shares for employee purchases. At the same annual meeting, shareholders re-elected five Class I directors for two-year terms, backed 2025 executive compensation on an advisory basis, and ratified KPMG LLP as independent auditor for 2026, collectively reinforcing management’s authority, employee incentive structures, and governance continuity.
The approvals of the new equity and employee stock purchase plans expand Sarepta’s capacity to issue stock-based compensation and support employee ownership, potentially strengthening talent retention in a competitive biotech labor market. Strong support for the plans and for the director slate, alongside the ratification of KPMG, signals broad shareholder alignment with the company’s current strategic direction and governance framework.
The most recent analyst rating on (SRPT) stock is a Hold
with a $19.00 price target.
To see the full list of analyst forecasts on Sarepta Therapeutics stock,
see the SRPT Stock Forecast page.
Spark’s Take on SRPT Stock
According to Spark, TipRanks’ AI Analyst, SRPT is a Neutral.
SRPT scores moderately due to improving but still volatile financial performance (notably inconsistent revenue/margins and uneven cash conversion). The latest earnings call adds support via reiterated guidance, strong margins, and profitability messaging, but is tempered by Alevitus demand/recovery uncertainty and lumpy/non-cash revenue items. Technicals are mixed with only modest momentum, while the very low P/E provides some valuation cushion amid elevated execution and regulatory risk.
To see Spark’s full report on SRPT stock,
click here.
More about Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing genetic medicines, including RNA-targeted therapeutics and gene therapies, primarily for rare neuromuscular diseases. The company targets conditions such as Duchenne muscular dystrophy, aiming to address high unmet medical needs in specialized patient populations.
Average Trading Volume: 3,089,297
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.72B
For detailed information about SRPT stock, go to TipRanks’ Stock Analysis page.
